Scinai Immunotherapeutics (SCNI) Invested Capital (2018 - 2025)

Scinai Immunotherapeutics has disclosed Invested Capital across 8 years of filings, most recently posting $8.6 million for Q4 2025.

• Invested Capital for Q4 2025 came in at $8.6 million, down 17.08% year-over-year; the trailing twelve-month figure through Dec 2025 was $8.6 million (down 17.08% YoY), and the FY2025 annual result was $8.6 million, down 17.08% from the prior year.
• Invested Capital came in at $8.6 million for Q4 2025 at Scinai Immunotherapeutics, up from $497000.0 in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $6.0 billion in Q2 2021 to a low of -$4.8 million in Q1 2023.
• The 5-year median for Invested Capital is $697000.0 (2022), against an average of $710.6 million.
• Across the five-year window, Invested Capital surged 23850.72% in 2022 and plunged 636.23% in 2023, its largest moves.
• Scinai Immunotherapeutics' Invested Capital stood at $1.4 million in 2021, then slumped by 201.55% to -$1.4 million in 2022, then tumbled by 202.83% to -$4.2 million in 2023, then surged by 349.25% to $10.4 million in 2024, then decreased by 17.08% to $8.6 million in 2025.
• The last three Invested Capital figures came in at $8.6 million (Q4 2025), $497000.0 (Q2 2025), and $10.4 million (Q4 2024), per Business Quant data.